GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » Additional Paid-In Capital

PDS Biotechnology (STU:EU6) Additional Paid-In Capital : €196.98 Mil(As of Mar. 2025)


View and export this data going back to 2016. Start your Free Trial

What is PDS Biotechnology Additional Paid-In Capital?


PDS Biotechnology's quarterly additional paid-in capital increased from Sep. 2024 (€176.73 Mil) to Dec. 2024 (€192.05 Mil) and increased from Dec. 2024 (€192.05 Mil) to Mar. 2025 (€196.98 Mil).

PDS Biotechnology's annual additional paid-in capital increased from Dec. 2022 (€137.40 Mil) to Dec. 2023 (€156.46 Mil) and increased from Dec. 2023 (€156.46 Mil) to Dec. 2024 (€192.05 Mil).

PDS Biotechnology Additional Paid-In Capital Historical Data

The historical data trend for PDS Biotechnology's Additional Paid-In Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PDS Biotechnology Additional Paid-In Capital Chart

PDS Biotechnology Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Additional Paid-In Capital
Get a 7-Day Free Trial Premium Member Only Premium Member Only 58.29 109.66 137.40 156.46 192.05

PDS Biotechnology Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Additional Paid-In Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 176.89 180.54 176.73 192.05 196.98

PDS Biotechnology Additional Paid-In Capital Calculation

Capital that a company raises in a financing round in excess of the capital's par value. The account represents the excess paid by an investor over the par-value price of a stock issue. Additional paid-in-capital can arise from issuing either preferred or common stock.

Additional Paid-In Capital is calculated as

Additional Paid-In Capital=(Issue Price-Par Value)* Shares Outstanding (Diluted Average)

PDS Biotechnology Additional Paid-In Capital Related Terms

Thank you for viewing the detailed overview of PDS Biotechnology's Additional Paid-In Capital provided by GuruFocus.com. Please click on the following links to see related term pages.

PDS Biotechnology Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PDS Biotechnology Corp (STU:EU6) » Definitions » Additional Paid-In Capital
Comparable Companies
INO AURX JSPR VERU CRVO ADAP TNYA VTGN EPIX IGMS VRTX ASX:CSL REGN XKRX:207940 ALNY XBRU:ARGX XBRU:UCB ONC XKRX:068270 BNTX
Traded in Other Exchanges
PDSB:USA
Address
303A College Road, East Princeton, NJ, USA, 08540
Website
https://www.pdsbiotech.com
PDS Biotechnology Corp operates as a clinical stage biotechnology company, principally involved in drug discovery in the United States. It is engaged in the treatment of various early-stage and late-stage cancers, including head and neck cancer, prostate cancer, breast cancer, cervical cancer, anal cancer, and other cancers. Its products are based on the proprietary Versamune platform technology, which activates and directs the human immune system to unleash a powerful and targeted attack against cancer cells.

PDS Biotechnology Headlines

No Headlines